Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice
American Journal of Hematology · 2026-09 · 101 (9) · 2105-2122
DOI: 10.1002/ajh.70391 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 04.06.2026. Verfasst von Shahla Vilcassim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Cancer Research, Hudson Institute of Medical Research, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Membrane Proteins, Serine Endopeptidases, Myelodysplastic Syndromes, RNA, Small Interfering. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Silence Therapeutics Plc, London, UK, mRNA Victoria Research Acceleration Fund (mVRAF), Australia, Royal Golden Jubilee PhD Research Scholarship, The National Research Council of Thailand (NRCT), and The Thailand Research Fund (TRF).
Abstract (Originalsprache)
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Despite advances in supportive and targeted therapies, disease‐modifying interventions remain limited. Iron overload is increasingly recognized as a key driver of disease progression, amplifying oxidative stress and inflammation while impairing hematopoietic function. However, the mechanisms by which sustained iron excess contributes to disease evolution remain poorly understood. Hepcidin, the master regulator of systemic iron homeostasis, is produced by hepatocytes in response to iron and inflammatory cues and is negatively regulated by transmembrane protease serine 6 (TMPRSS6). Targeting TMPRSS6 to increase endogenous hepcidin offers a promising strategy to restrict iron overload and its inflammatory consequences. Here, we investigated hepatocyte‐targeted silencing of Tmprss6 using a GalNAc‐conjugated siRNA (SLN124) in the NUP98–HOXD13 (NHD13) mouse model of MDS. MDS and wild‐type mice received monthly subcutaneous SLN124 (3 mg/kg) or oral deferiprone (1.25 mg/mL). Iron burden in MDS mice strongly correlated with ASC‐speck formation in CD45 + hematopoietic cells, consistent with inflammasome activation. Both SLN124 and deferiprone reduced tissue iron deposition and ASC‐speck abundance, with SLN124 producing the most pronounced effect. Long‐term SLN124 treatment delayed disease progression and significantly prolonged survival, with 30% of treated mice surviving beyond 450 days compared with complete mortality by Day 420 in controls and deferiprone‐treated mice. These findings demonstrate that Tmprss6 inhibition via SLN124 suppresses iron‐driven inflammation, and mitigated disease progression in MDS mice, establishing TMPRSS6 silencing as a promising disease‐modifying therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre of Cancer Research, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.
- School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
- Graduate Program in Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand.
- Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
- Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
- Faculty of Medicine, Praboromarajchanok Institute, Ministry of Public Health, Nonthaburi, Thailand.
ORCID-Profile: Pornthip Chaichompoo, Jim Vadolas
Förderung
- Silence Therapeutics Plc, London, UK
- mRNA Victoria Research Acceleration Fund (mVRAF), Australia
- Royal Golden Jubilee PhD Research Scholarship, The National Research Council of Thailand (NRCT), and The Thailand Research Fund (TRF)
- Silence Therapeutics
Zitieren
APA
Vilcassim, S., Pholngam, N., Thubthed, R., Nualkaew, T., Svasti, S., Chaichompoo, P., Kysenius, K., Crouch, P. J., Dames, S., Eisermann, M., Martinez, A., Schaeper, U., Vadolas, J., & Grigoriadis, G. (2026). Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice. American Journal of Hematology, 101(9), 2105-2122. https://doi.org/10.1002/ajh.70391
Vancouver
Vilcassim S, Pholngam N, Thubthed R, Nualkaew T, Svasti S, Chaichompoo P, et al. Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice. American Journal of Hematology. 2026;101(9):2105-2122. doi:10.1002/ajh.70391
BibTeX
@article{Vilcassim2026,
author = {Vilcassim, Shahla and Pholngam, Nuttanan and Thubthed, Rattanawan and Nualkaew, Tiwaporn and Svasti, Saovaros and Chaichompoo, Pornthip and Kysenius, Kai and Crouch, Peter J and Dames, Sibylle and Eisermann, Mona and Martinez, Alberto and Schaeper, Ute and Vadolas, Jim and Grigoriadis, George},
title = {Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {9},
pages = {2105--2122},
doi = {10.1002/ajh.70391}
}
EUVIMED